If the flow in the AVM is in the other direction, portal venous blood flows directly into the veins rather than running through the liver; this may lead to hepatic encephalopathy ( confusion due to portal waste products irritating the brain ).
42.
In the 1950s, several reports enumerated the numerous abnormalities reported previously, and confirmed the previously enunciated theory that metabolic impairment and portosystemic shunting are the underlying mechanism behind hepatic encephalopathy, and that the nitrogen-rich compounds originate from the intestine.
43.
Other liver-related complications ( portal hypertension, esophageal varices, ascites, hepatic encephalopathy ) are treated with the same modalities as used in cirrhosis, although the use of transjugular intrahepatic portosystemic shunt treatment is discouraged due to the lack of documented benefit.
44.
ALCAR has been studied in hepatic encephalopathy, a complication of cirrhosis involving neuropsychiatric impairment; ALCAR improves blood ammonia levels and generates a modest improvement in psychometric scores but does not resolve the condition it may play a minor role in managing the condition.
45.
Minimal hepatic encephalopathy reduces quality of life by impairing work activities, social interactions, and driving, but it does not affect basic daily life activities such as dressing, personal hygiene, eating, shopping, answering the phone, or taking public transportation.
46.
Liver cirrhosis may lead to portal hypertension, ascites ( accumulation of fluid in the abdomen ), easy bruising or bleeding, varices ( enlarged veins, especially in the stomach and esophagus ), jaundice, and a syndrome of cognitive impairment known as hepatic encephalopathy.
47.
Hepatic encephalopathy type B may arise in those who have undergone a TIPS procedure; in most cases this resolves spontaneously or with the medical treatments discussed below, but in a small proportion of about 5 %, occlusion of the shunt is required to address the symptoms.
48.
Severe adverse events identified during the EMILIA trial included hepatotoxicity ( liver damage ), including rare cases of liver failure, hepatic encephalopathy, and nodular regenerative hyperplasia; heart damage ( dysfunction of the left ventricle ); interstitial lung disease, including acute interstitial pneumonitis; thrombocytopenia; and peripheral neuropathy.
49.
Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA, for a target drug candidate, KLS-13019 to treat Hepatic encephalopathy and CTE, an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.
50.
The prospective exclusive license territory may be worldwide, and the field of use may be limited to : The development and sale of cannabinoid ( s ) and cannabidiol ( s ) based therapeutics as antioxidants and neuroprotectants for use and delivery in humans, for the treatment of hepatic encephalopathy, as claimed in the Licensed Patent Rights.
